Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CELU – Celularity Inc.

CELU — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

2.86

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

1.22

Target Price

6

Analyst Recom

2

Performance Q

-7.58

Upside

-3,648.4%

Beta

0.75

Ticker: CELU




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-02-27CELU1.2130.010.00547
2026-03-02CELU1.20.010.00554
2026-03-03CELU1.150.01999.99556
2026-03-04CELU1.220.01999.99556
2026-03-05CELU1.20.01999.99556
2026-03-06CELU1.210.01999.99556
2026-03-09CELU1.250.01999.99556
2026-03-10CELU1.370.010.25556
2026-03-11CELU1.30.010.25556
2026-03-12CELU1.270.010.25556
2026-03-13CELU1.270.010.25556
2026-03-17CELU1.270.010.25556
2026-03-18CELU1.25N/AN/A0
2026-03-19CELU1.28N/AN/A0
2026-03-20CELU1.21N/AN/A0
2026-03-23CELU1.220.010.00538
2026-03-24CELU1.280.010.00538
2026-03-25CELU1.220.010.00538
2026-03-26CELU1.210.010.00538
2026-03-27CELU1.210.010.00538
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-02-27CELU1.22- - -
2026-03-02CELU1.21- - -
2026-03-03CELU1.15- - -
2026-03-04CELU1.26- - -
2026-03-05CELU1.22- - -
2026-03-06CELU1.21- - -
2026-03-09CELU1.26- - -
2026-03-10CELU1.39- - -
2026-03-11CELU1.28- - -
2026-03-12CELU1.26- - -
2026-03-13CELU1.23- - -
2026-03-17CELU1.27- - -
2026-03-18CELU1.26- - -
2026-03-19CELU1.26- - -
2026-03-20CELU1.20- - -
2026-03-23CELU1.22- - -
2026-03-24CELU1.28- - -
2026-03-25CELU1.21- - -
2026-03-26CELU1.18- - -
2026-03-27CELU1.22- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-02-27CELU0.000.102.35
2026-03-02CELU0.000.102.35
2026-03-03CELU0.000.102.35
2026-03-04CELU0.000.102.35
2026-03-05CELU0.000.102.35
2026-03-06CELU0.000.102.35
2026-03-09CELU0.000.102.35
2026-03-10CELU0.000.102.35
2026-03-11CELU0.000.102.04
2026-03-12CELU0.000.102.04
2026-03-13CELU0.000.102.04
2026-03-17CELU0.000.102.04
2026-03-18CELU0.000.102.04
2026-03-19CELU0.000.102.04
2026-03-20CELU0.000.102.04
2026-03-23CELU0.000.102.04
2026-03-24CELU0.000.102.04
2026-03-25CELU0.000.102.86
2026-03-26CELU0.000.102.86
2026-03-27CELU0.000.102.86
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

0.1

Beta

0.75

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

21

Growth Score

33

Sentiment Score

3

Actual DrawDown %

99.1

Max Drawdown 5-Year %

Target Price

6

P/E

Forward P/E

PEG

P/S

0.87

P/B

P/Free Cash Flow

EPS

-3.33

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-198.75

Relative Volume

0.15

Return on Equity vs Sector %

374

Return on Equity vs Industry %

390.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

CELU Healthcare
$1.22
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
15/25
Volume
11/15
Valuation
12/20
TP/AR
1/10
Options
7/10
RSI
47
Range 1M
41.7%
Sup Dist
4.9%
🚀
Momentum Growth
Ride accelerating trends
N/A
13 /100
WEAK
Momentum
0/25
Growth
3/30
Estimates
0/20
Inst/Vol
2/15
Options
8/10
EPS Yr
0%
EPS NY
0%
52W%
6.3%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +391.8% upside
Quality
5/30
Valuation
16/30
Growth
0/25
Stability
5/10
LT Trend
1/5
Upside
+391.8%
Quality
21
Celularity Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 123
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
CELU

Latest News

Caricamento notizie per CELU
stock quote shares CELU – Celularity Inc. Stock Price stock today
news today CELU – Celularity Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CELU – Celularity Inc. yahoo finance google finance
stock history CELU – Celularity Inc. invest stock market
stock prices CELU premarket after hours
ticker CELU fair value insiders trading